MiniMed™ 780G System Achieves Time-in-Range Goals
A recent real-world analysis revealed that users of the MiniMed™ 780G system reached the American Diabetes Association (ADA) recommended time-in-range (TIR) goals, even on days when they missed their mealtime boluses. This study utilized CareLink™ data, which showed a remarkable 76.3% TIR during days when boluses were not administered. This analysis emphasizes the effectiveness of the MiniMed™ 780G system, particularly with its SmartGuard™ technology, even under challenging circumstances.
Understanding the Burden of Mealtime Management
For individuals managing type 1 diabetes, mealtimes often present significant challenges. The pressure to make accurate decisions about carbohydrate intake and insulin dosage can lead to considerable anxiety and stress. A 2024 study highlighted that young users of automated insulin delivery (AID) systems missed an average of 2.2 boluses daily, with each missed bolus corresponding to nearly a 10% reduction in TIR. Such findings underscore the complexity and stress of managing diabetes during meals.
Challenges with Missed Boluses
According to Dr. Jennifer McVean, Senior Medical Affairs Director at Medtronic Diabetes and lead investigator of the study, real-world data demonstrates that missed boluses are a common occurrence. Despite the requirement for meal announcement within the system's labeling, this analysis revealed that 71.2% of users still achieved ADA-recommended TIR figures on days when they forgot to administer their boluses, thanks to optimized settings.
Study Design and Key Findings
The study scrutinized the global CareLink user data for 369,467 users of the MiniMed™ 780G insulin pump who had at least 10 days of no bolusing behavior. Among them, 54,553 users were observed from January 2, 2020, to March 31, 2025. The comparison of glycemic outcomes between those who utilized recommended optimal settings and those who did not indicates significant advantages throughout different age groups
Statistical Improvements and Outcomes
Results showed a notable difference in outcomes between users following recommended optimal settings versus those using alternate settings. Specifically, users on optimal settings achieved:
- TIR of 76.3% compared to 69.3% for those not using optimal settings.
- Mean sensor glucose levels of 149 mg/dL, compared to 160 mg/dL.
- A glucose management indicator of 6.9%, versus 7.1% for non-optimal users.
- Over 61% of optimal setting users met all three ADA-recommended glycemic targets, while only 36.6% of other setting users met the same benchmarks.
These impressive findings showcase the capabilities of the MiniMed™ 780G system, highlighting its potential to alleviate the daily challenges faced by people living with diabetes.
Empowering Diabetes Management
Que Dallara, Executive Vice President and President of Medtronic Diabetes, commented on the implications of these findings, expressing a commitment to developing technology that adapts to the real-life situations faced by diabetes patients. By providing advanced tools like the MiniMed™ 780G, Medtronic aims to enhance the quality of life for those dealing with the complexities of diabetes care.
About Medtronic Diabetes
At Medtronic Diabetes, we focus on making diabetes manageable. With over 40 years of innovation in diabetes care technology, our goal is to support users with continuous data and intelligent solutions, helping them lead fulfilled lives.
Frequently Asked Questions
What is the MiniMed™ 780G system?
The MiniMed™ 780G is an advanced insulin delivery system designed for people managing diabetes. It adjusts insulin delivery automatically based on real-time glucose readings.
How does the system support users who miss boluses?
It incorporates SmartGuard™ technology that auto-corrects blood glucose levels based on sensor readings, which helps maintain TIR even when boluses are missed.
What are the key features of recommended optimal settings?
These settings establish target glucose levels and active insulin times to optimize insulin delivery, leading to improved glycemic outcomes.
How does missing a bolus affect glycemic management?
Missing a bolus can lead to significant spikes in blood glucose levels, negatively impacting overall diabetes management and average TIR.
What ongoing innovations is Medtronic working on?
Medtronic is continually researching and developing newer technologies to improve diabetes management, including advanced sensing and dosing systems.
